| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Chairperson And CEO | CEO And Chairperson +3 more
6 companies
Chen Bihua is a Director, 10% Owner at ERAS, with reported holdings spanning 6 companies. Recent filings cover 47 purchases and 6 sales. Those positions are worth an estimated $254.1M at current prices.
Our model assigns Chen Bihua a middling insider score of 56/100, based on 18 past trades. Over a 12-month horizon, 31.3% of those trades were profitable, with an average 12-month return of -3.4%.
Chen Bihua's largest disclosed position is in BMEA, worth about $107.1M. Net of sales, the recent Form 4 record there shows accumulation of 1,300,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 5, 2022 | MLTX Moonlake Immunotherapeutics | 10% Owner | Buy | 2,850,000 | $10.00 | $28,500,000.00 | New | -57.6% | +53.3% | |
| Aug 10, 2021 | ERAS Erasca, Inc. | Director | Buy | 200,000 | $22.10 | $4,420,000.00 | +1.9% | -3.9% | -52.9% | |
| Jul 26, 2021 | ERAS Erasca, Inc. | Director | Sell | 200,000 | $18.77 | $3,753,000.00 | -1.9% | +2.2% | -57.8% | |
| Jul 20, 2021 | ERAS Erasca, Inc. | Director | Buy | 950,000 | $16.00 | $15,200,000.00 | +9.9% | -11.7% | -59.0% | |
| Apr 20, 2021 | BMEA Biomea Fusion, Inc. | Director | Buy | 900,000 | $17.00 | $15,300,000.00 | +39.6% | -19.4% | -75.7% | |
| Oct 22, 2020 | MLTX Moonlake Immunotherapeutics | CEO And Chairman | Buy | 430,000 | $10.00 | $4,300,000.00 | New | - | - |